In stock Batch Verification Description Retatrutide Canada 30mg Laboratory Research Reagent Retatrutide Canada 30mg is supplied as lyophilized material intended for non-clinical laboratory research by qualified facilities and trained personnel
Retatrutide safety and side effects The Phase 2 clinical trial results showed an incidence of adverse events in 70% of patients in the placebo group and 73 to 94% in the retatrutide group
To mitigate potential discrepancies in baseline characteristics between the two study groups, we comprehensively integrated and algorithmically selected high-dimensional covariates assessed within 1 year before the index time
Research Compound Summary Compound: Retatrutide CAS Number: 2381089-83-2 Molecular Formula: C205H320N56O63S2 Purity: 99.71% (HPLC-UV verified) Third-Party Testing: Testides Analytical (independent lab, Toronto) COA Download: View Full COA (PDF) Report: DBAV-RETA-10-062726 Source: Canadian manufactured Shipping: Same-day from our BC facility Retatrutide peptide Canada: a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously
Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes
It is believed to have several health benefits
